Credit Suisse Upgrades Allergan To Outperform, Raises PT To $91

August 16, 2011 5:50 AM | 8 seconds read |
Credit Suisse has upgraded Allergan AGN from Neutral to Outperform and has raised the price target from $81 to $91.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: UpgradesPrice TargetAnalyst RatingsCredit SuisseHealth CarePharmaceuticals
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!